This week, Halle and Michael sit down for a special in-person listener Q&A to answer a range of founder questions you submitted.

Breakthrough blood tests that can flag dozens of cancers before symptoms appear are gaining momentum, yet questions remain about accuracy, equity, and how these tools will fit into routine care.

In this episode, Steve talks with Helmy Eltoukhy, co-founder and co-CEO of Guardant Health, a $14 billion publicly-traded precision oncology company. The conversation explores the science behind cell-free DNA, the rise of blood-based cancer screening, and the broader shift toward data-driven diagnostics.

Physicians now face a world where search bars, chat apps, and large AI models are becoming many people’s first stop for health questions, long before they enter a clinic.

Former Google Chief Health Officer and national health IT leader Dr. Karen DeSalvo joins us to unpack what this shift means for clinicians, regulators, and patients, and why 15% of daily Google searches are questions no one has ever asked before.

Over 3 million clinicians around the world depend on UpToDate to guide patient care, and now the gold standard in clinical decision support is integrating generative AI. But in a world where AI models often hallucinate, how do you build something that doctors can actually trust?

One in four Americans is enrolled in Medicaid, yet the system designed to support them is constantly at risk—underfunded, politically vulnerable, and often overlooked.

Dexcom generates more than $4 billion in annual revenue and has a market cap north of $30 billion, making it one of the biggest digital health companies in the world. And it all started with a better way to measure blood sugar.

Over half of Americans now live with at least one chronic condition, yet our healthcare system still revolves around episodic, reactionary care instead of continuous, coordinated support.

Over 160 million Americans are served by Optum, yet many still don’t fully understand what it actually does—or why it matters.

The Mark Cuban Cost Plus Drug Company